Syngene International Limited Earnings Summary — Q4 FY2026
Syngene Reports Revenue Growth in Q4 but Significant Margin Compression and Year-on-Year Profit Decline
Key Takeaways
- Revenue for Q4 FY2026 reached ₹1,036 Cr, showing a recovery trend from previous quarters but marginal yearly growth.
- Net profit saw a sharp YoY decline of 19% compared to the ₹183 Cr reported in the same quarter last year.
- Operating profit margins (OPM) have stabilized at 29% in Q4, up from 23% in Q3, but still significantly lower than historical 30-35% levels.
- Significant recovery in profitability is noted sequentially (QoQ) following a very weak Q3 FY2026 (₹15 Cr profit).
- Capital expenditure remains high with CWIP at ₹1,040 Cr as the company transitions toward CDMO manufacturing.
- The balance sheet remains strong with a continued reduction in total borrowings to ₹458 Cr.
- Full-year FY2026 performance shows a marked deceleration in profit growth (-21% TTM).
Management Guidance
Management remains focused on transitioning into a multi-disciplinary partner for global pharma, though recent growth has cooled. There is an ongoing shift toward lower-margin manufacturing segments.
Sentiment Shift
Deteriorating
Outlook
The company is navigating a challenging transition from pure CRO to a capital-intensive CDMO model. While debt reduction is positive, declining ROE and profit growth suggest a cooling of the stock's premium valuation narrative.
← Back to Syngene International Limited AI analysis
Unlock the full report
Deep-dive sections, financial charts, AI chat and PDF export are available with Premium.
This summary is AI-generated from Syngene International Limited's latest annual report and public disclosures. It is for informational purposes only and is not investment advice.